samedan logo
 
 
spacer
home > pmps > winter 2008 > optimising profitability potential
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Optimising Profitability Potential

Andre Grigjanis at IBS Pharma tells us how to gain increased profitability with inventory optimisation

One of the largest capital expenses for pharmaceutical wholesalers is stock. Finding a balance – ensuring that products are available when customers need them, yet do not become an excess product – is critical for a successful business. However, most companies make these decisions without looking at the full picture. They don’t consider how to plan accurately for demand on the basis of detailed purchasing histories, or how to handle returns effectively. An inventory optimisation solution is designed to help companies overcome these issues in order to enhance customer service and lower operational costs.

WHAT IS INVENTORY OPTIMISATION?

Inventory optimisation tools help companies to make reliable decisions regarding product replenishment. Making the correct decisions raises efficiency and profitability by improving the forecasting of future demand and by creating a more economical stock holding. The physical distribution network is the basis for an effective inventory and supply chain management solution. Inventory optimisation defines a unique multi-level distribution network for each product, covering where the product is stored: either at an external supplier or within internal production or warehouse locations. Replenishment recommendations created by an inventory optimisation system can help companies decide when to buy, produce or ship goods between warehouses, thereby optimising the total inventory situation.

All pharmaceutical wholesalers have fastmoving products, such as aspirins, that they need to be available all the time. However, there may be some specific drugs that are required much more rarely. They may be expensive, but if a customer asks for them and they are not available, the customer is not going to wait. A dedicated solution for optimising inventories helps to ensure that the right products are available when and where they are needed. In addition, by automating many of the procedures required for effective inventory management, the people who deal with purchasing can concentrate on more profitable items.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andre Grigjanis is Vice President, Pharma at IBS. After spending several years in international IT services for IBM and other software companies, for the last seven years he has concentrated on business development, business processes and the supply chain within the pharmaceutical industry. His experience has given him an excellent overview of trends in the pharmaceutical distribution business as well as current and future demands. As Vice President, Pharma, he represents the IBS Group at IFPW (International Federation of Pharmaceutical Wholesalers) and GIRP (European Association of Pharmaceutical Full-line Wholesalers) meetings and congresses. Andre has a Master’s Degree in Electronic Engineering and Economics
spacer
Andre Grigjanis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) With EC Authorisation of Bispecific Antibody for the Treatment of Patients With Multiple Myeloma

BEERSE, BELGIUM, 24 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI®▼ (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.1 Today’s milestone marks the first approval worldwide for teclistamab, a bispecific antibody that redirects CD3-positive T-cells to B-cell maturation antigen (BCMA)-expressing myeloma cells to induce the killing of tumour cells.1
More info >>

White Papers

Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation

The Avoca Group

So often, inspections are a major source of stress in the clinical trial environment. This is especially true when processes involved in preparing for an inspection are reactive. But, it doesn’t have to be that way. Using industry-leading practices and resources enables a proactive approach to mitigate—or even eliminate—the pain points associated with preparing for inspections.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement